The Impact of COVID-19 Pandemic on the Smoking Behaviour of Young Smokers and the Youth Quitline Service in Hong Kong

November 2, 2020 updated by: Dr. LI William Ho Cheung, The University of Hong Kong

The Impact of Coronavirus Disease (COVID-19) Pandemic on the Smoking Behaviour of Young Smokers and the Youth Quitline Service in Hong Kong: A Survey Study

The aims of the present study are:

  1. To explore the impact of COVID-19 pandemic on the smoking behavior of youth smokers
  2. To explore the impact of COVID-19 pandemic on the Youth Quitline service in Hong Kong

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

The coronavirus disease 2019 (COVID-19) pandemic has spread rapidly across the globe. According to World Health Organization (WHO), due to the harmful effects on the lungs and the possible viral transmission from fingers to mouth during smoking, tobacco use is considered a major risk factor for developing COVID-19. Both tobacco use and COVID-19 can cause damage to the cardiovascular and respiratory systems. Smokers infected with COVID-19 are at higher risk of developing severe COVID-19 symptoms or death than non-smokers.

The Hong Kong SAR (HKSAR) government has announced different regulations to combat the spread of COVID-19 since late January 2020, which significantly affect the working patterns and everyday lives of people. It remains unknown how smoking habits and smoking cessation services are being affected during the pandemic.

Study Type

Observational

Enrollment (Anticipated)

150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Hong Kong
      • Hong Kong, Hong Kong, Pokfulam
        • Recruiting
        • The University of Hong Kong

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 second to 25 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Youth smokers

Description

Inclusion Criteria:

  • Hong Kong resident aged 25 or below
  • Able to communicate in Chinese (Cantonese)
  • Smoked in the past 30 days

Exclusion Criteria:

  • Have difficulty to communicate via telephone

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Youth smokers
Participants of Youth Quitline
Other: Telephone survey
Participants will be asked to respond to a survey regarding their knowledge about the relationship between smoking and COVID-19, their smoking behaviors and readiness to quit during the pandemic.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Smoking behaviors
Time Frame: Baseline
Change in smoking behaviors of youth smokers during the pandemic
Baseline
Knowledge
Time Frame: Baseline
Knowledge regarding the relationship between COVID-19 and smoking
Baseline
Readiness to quit
Time Frame: Baseline
Change in motivation to quit during the pandemic
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The University of Hong Kong

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 24, 2020

Primary Completion (Anticipated)

December 30, 2021

Study Completion (Anticipated)

December 30, 2021

Study Registration Dates

First Submitted

April 22, 2020

First Submitted That Met QC Criteria

April 22, 2020

First Posted (Actual)

April 24, 2020

Study Record Updates

Last Update Posted (Actual)

November 4, 2020

Last Update Submitted That Met QC Criteria

November 2, 2020

Last Verified

November 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NCT02758028_1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

The relevant anonymized patient level data, full dataset, technical appendix, and statistical code are available on reasonable request. The approval from the Principal Investigator for the purpose of data use is required.

IPD Sharing Time Frame

After the project is completed and the results of the project has been published.

IPD Sharing Access Criteria

Request could be sent to Principal Investigator (william3@hku.hk)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe